Lapatinib plus esomeprazole is a combination therapy under investigation for metastatic ErbB2-positive breast cancer. The regimen aims to enhance lapatinib's pharmacokinetics and efficacy. One completed Phase 1 trial has evaluated its safety and pharmacokinetic profile.